Showing results (731-740 of 1,598) with videos related to
Sort By:
Pageof 160
Cancer Journal (Sudbury, Mass.)|June 10, 2008
Antibodies and hematologic malignanciesMitchell R SmithCancer Journal (Sudbury, Mass.)|July 24, 2019
Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical TrialsLaura M Yee, Lisa M McShane, Boris Freidlin, et al.Cancer Journal (Sudbury, Mass.)|January 24, 2017
Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These DrugsKimberly Loo, Adil I DaudCancer Journal (Sudbury, Mass.)|January 24, 2017
Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy in Need of Further InvestigationFreddy E Escorcia, Michael A Postow, Christopher A BarkerCancer Journal (Sudbury, Mass.)|January 24, 2017
Intratumoral Approaches for the Treatment of MelanomaPraveen K Bommareddy, Ann W Silk, Howard L KaufmanCancer Journal (Sudbury, Mass.)|October 15, 2009
Tumor shrinkage and objective response rates: gold standard for oncology efficacy screening trials, or an outdated end point?Penelope Bradbury, Lesley SeymourCancer Journal (Sudbury, Mass.)|October 15, 2009
Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacySen H Zhuang, Liang Xiu, Yusri A ElsayedCancer Journal (Sudbury, Mass.)|October 15, 2009
Other paradigms: better treatments are identified by better trials: the value of randomized phase II studiesManish R Sharma, Michael L Maitland, Mark J RatainCancer Journal (Sudbury, Mass.)|April 15, 2017
Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in GlioblastomaTanner M Johanns, Gavin P DunnPageof 160